The scientist’s investigation covers issues in Internal medicine, Endocrinology, Antagonist, Amygdala and Central nucleus of the amygdala. His research related to Anxiogenic, Receptor, Neuropeptide, Corticotropin-releasing hormone and Alpha might be considered part of Internal medicine. His work investigates the relationship between Endocrinology and topics such as Urocortin that intersect with problems in Emotionality.
He has researched Antagonist in several fields, including Stressor, Neuroscience, Endogeny and Microinjection. His Amygdala research incorporates elements of Elevated plus maze and Anesthesia. His Central nucleus of the amygdala research includes elements of Basal ganglia and Striatum.
His scientific interests lie mostly in Internal medicine, Endocrinology, Neuroscience, Receptor and Antagonist. Internal medicine connects with themes related to Epilepsy in his study. His Endocrinology research is multidisciplinary, incorporating perspectives in Stressor, Urocortin and Anxiogenic.
His Hippocampus, Cognition and Stimulus study in the realm of Neuroscience interacts with subjects such as Phenotype. His Corticotropin-releasing hormone receptor 1, Sauvagine and Steroid hormone study, which is part of a larger body of work in Receptor, is frequently linked to Gene knockdown, bridging the gap between disciplines. His study looks at the relationship between Antagonist and topics such as Amygdala, which overlap with Elevated plus maze.
Stephen C. Heinrichs mostly deals with Epilepsy, Internal medicine, Endocrinology, Neuroscience and Neuropeptide. His Epilepsy research is multidisciplinary, relying on both Emotionality, Neglect and Physiology. Stephen C. Heinrichs focuses mostly in the field of Internal medicine, narrowing it down to matters related to Stressor and, in some cases, Litter and Odor.
His work in Endocrinology is not limited to one particular discipline; it also encompasses Neurological disorder. When carried out as part of a general Neuroscience research project, his work on Hippocampus and Cognition is frequently linked to work in Phenotype and False positive paradox, therefore connecting diverse disciplines of study. His studies in Neuropeptide integrate themes in fields like Social stress, Corticosterone, Corticotropin-releasing hormone and Glucocorticoid.
Stephen C. Heinrichs focuses on Epilepsy, Endocrinology, Internal medicine, Neuroscience and Emotionality. His work in the fields of Ketogenic diet overlaps with other areas such as Rett syndrome. His biological study spans a wide range of topics, including Anticonvulsant and Anesthesia.
Stephen C. Heinrichs integrates many fields in his works, including Internal medicine and Toxin. Stephen C. Heinrichs interconnects Neuropeptide and Neglect in the investigation of issues within Neuroscience. The Emotionality study combines topics in areas such as Cognition and Aggression.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A role for corticotropin releasing factor and urocortin in behavioral responses to stressors.
George F. Koob;Stephen C. Heinrichs.
Brain Research (1999)
Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal.
Stefanie Rassnick;Stephen C. Heinrichs;Karen T. Britton;George F. Koob.
Brain Research (1993)
Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior
Mary P. Stenzel-Poore;Stephen C. Heinrichs;Serge Rivest;George F. Koob.
The Journal of Neuroscience (1994)
Corticotropin-releasing factor in brain: A role in activation, arousal, and affect regulation
Stephen C. Heinrichs;George F. Koob.
Journal of Pharmacology and Experimental Therapeutics (2004)
Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action.
Stephen C. Heinrichs;Emilio Merlo Pich;Klaus A. Miczek;Karen T. Britton.
Brain Research (1992)
Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat
S B Caine;S C Heinrichs;V L Coffin;G F Koob.
Brain Research (1995)
The Role of Corticotropin‐Releasing Factor in Behavioural Responses to Stress
George F. Koob;Stephen C. Heinrichs;Emilio Merlo Pich;Frédérique Menzaghi.
Ciba Foundation symposium (1993)
Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease
Dominic P. Behan;Stephen C. Heinrichs;Juan C. Troncoso;Xin Jun Liu.
Nature (1995)
Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior
S.C Heinrichs;J Lapsansky;T.W Lovenberg;E.B De Souza.
Regulatory Peptides (1997)
Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal.
Heinrichs Sc;Menzaghi F;Schulteis G;Koob Gf.
Behavioural Pharmacology (1995)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institute on Drug Abuse
Salk Institute for Biological Studies
Scripps Research Institute
Tufts University
Salk Institute for Biological Studies
University of California, San Diego
Salk Institute for Biological Studies
Oregon Health & Science University
Washington University in St. Louis
University of California, Irvine
Delft University of Technology
McGill University
Hong Kong Baptist University
Yunnan University
Ulsan National Institute of Science and Technology
Hebrew University of Jerusalem
University of Montpellier
University of Natural Resources and Life Sciences
University of Queensland
University of Stirling
University of Toronto
University of Padua
Icahn School of Medicine at Mount Sinai
University of British Columbia
Birkbeck, University of London
University of California, Los Angeles